As part of Health Canada’s initiative to update its approach to regulating self-care products, including non-prescription drugs (broadly, also including cosmetics and natural health products), and as a first step in advance of a regulatory proposal to simplify market access for non-prescription drug products, Health Canada has developed a Non-prescription Drug Action Plan.
The action plan introduces policy and operational solutions to remove barriers for getting non-prescription drugs (excluding ethical drugs, controlled substances, and biocides) to market, by removing repetitious and onerous requirements and introducing flexibilities for industry.
Short-term solutions were announced and effective December 2022, with updates relating to optional subheadings for the Canadian Drug Facts Table, product monograph and patient medication information leaflets, and label mock-up requirements. Medium- and long-term solutions are targeted for the end of 2023 and the end of 2024; Health Canada will publish further information once the work is completed, for example by way of notices.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Health Canada and the Competition Bureau commit to information sharing to combat false, misleading or deceptive health claims
On March 7, 2024, Health Canada published a Memorandum of Understanding (MOU) with the Competition Bureau (together, Participants) to advance their mutual interests and develop a framework of cooperat...Read More -
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Generic Submissions Under Review list will identify generic filers
On February 23, 2024, Health Canada announced that it will expand the information available on the Generic Submissions Under Review (GSUR) list.Read More